XOMA (XOMA Royalty) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

XOMA Royalty's net issuance of preferred for the three months ended in Dec. 2024 was $0.00 Mil. The number is 0, which means that XOMA Royalty has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

XOMA Royalty's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

XOMA Royalty Net Issuance of Preferred Stock Historical Data

The historical data trend for XOMA Royalty's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Net Issuance of Preferred Stock Chart

XOMA Royalty Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

24.60

40.00

XOMA Royalty Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

XOMA Royalty Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

XOMA Royalty Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA 0M26:UK

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Executives

Bradley Sitko	officer: Chief Investment Officer	C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Joseph M Limber	director	ACLARA BIOSCIENCES INC, 1288 PEAR AVE, MOUNTAIN VIEW CA 94043
Thomas M. Burns	officer: Chief Financial Officer	2910 SEVENTH STREET, BERKELEY CA 94710
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Owen Hughes	director, officer: Interim CEO	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
James R Neal	officer: VP Business Development	2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday	director	932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman	director	C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz	director	3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta	officer: Chief Business Officer	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian	director, officer: Director and CEO	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555